Mechanism of Two Classes of Cancer Mutations in the Phosphoinositide 3-Kinase Catalytic Subunit

Many human cancers involve up-regulation of the phosphoinositide 3-kinase PI3Kα, with oncogenic mutations identified in both the p110α catalytic and the p85α regulatory subunits. We used crystallographic and biochemical approaches to gain insight into activating mutations in two noncatalytic p110α d...

Full description

Saved in:
Bibliographic Details
Published in:Science (American Association for the Advancement of Science) Vol. 317; no. 5835; pp. 239 - 242
Main Authors: Miled, Nabil, Yan, Ying, Hon, Wai-Ching, Perisic, Olga, Zvelebil, Marketa, Inbar, Yuval, Schneidman-Duhovny, Dina, Wolfson, Haim J., Backer, Jonathan M., Williams, Roger L.
Format: Journal Article
Language:English
Published: Washington, DC American Association for the Advancement of Science 13-07-2007
The American Association for the Advancement of Science
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Many human cancers involve up-regulation of the phosphoinositide 3-kinase PI3Kα, with oncogenic mutations identified in both the p110α catalytic and the p85α regulatory subunits. We used crystallographic and biochemical approaches to gain insight into activating mutations in two noncatalytic p110α domains--the adaptor-binding and the helical domains. A structure of the adaptor-binding domain of p110α in a complex with the p85α inter--Src homology 2 (inter-SH2) domain shows that oncogenic mutations in the adaptor-binding domain are not at the inter-SH2 interface but in a polar surface patch that is a plausible docking site for other domains in the holo p110/p85 complex. We also examined helical domain mutations and found that the$\text{Glu}^{545}$to$\text{Lys}^{545}$(E545K) oncogenic mutant disrupts an inhibitory charge-charge interaction with the p85 N-terminal SH2 domain. These studies extend our understanding of the architecture of PI3Ks and provide insight into how two classes of mutations that cause a gain in function can lead to cancer.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:0036-8075
1095-9203
DOI:10.1126/science.1135394